Mario Balsa· @MarioBalsaMD · X·· 2 天前评分70
正文 · 原文
🚨 My top 4 #Melanoma #ESMO26 GC101 TIL: TILs without the full toxicity baggage?
Randomized phase II in >=2L anti-PD-1-resistant melanoma! Notably 73% acral/mucosal!!!
▪️PFS: 4.37 vs 1.61m (HR 0.44)
💥 ORR: 44% vs 8%
-Acral: ORR 45% vs 8%
-Mucosal: ORR 50% vs 0%
IL-2-free + reduced-intensity lymphodepletion 👀 and the discussant questioned whether 50% dose sintilimab really changes much…
@OncoAlert @OncoReporte @myESMO @_SEOM @GrupoMelanoma
900 浏览 · 10 赞 · 7 转发 · 2 回复
帖内回复
- Lude@Lude2025
@MarioBalsaMD @kainvests @Larvol @brunolarvol @SuyogCancer What about Iovance Amtagvi that’s an incredible drug curing cancer
- ONCO BRUNO@brunolarvol
@MarioBalsaMD @Larvol @SuyogCancer Hope we get to say hi 👋
来源：Mario Balsa · x.com